Approval · Notice of Compliance 37820 · 2026
VANRAFIA: Notice of Compliance 37820
Issued July 2, 2026
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 37820
- Date
- July 2, 2026
- Company
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- New Active Substance (NAS)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| VANRAFIA | 02569590 | Approved |
Medicinal ingredients
- ATRASENTAN HYDROCHLORIDE 0.75 MG per TAB